IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
This triple blend combines Tesamorelin (6 mg) and CJC-1295 without DAC (3 mg) — two GHRH (growth hormone–releasing hormone) analogs — with Ipamorelin (6 mg), a highly selective growth hormone secretagogue (ghrelin-receptor agonist). Hitting both the GHRH receptor and the GHS receptor at once is researched for amplified yet naturally pulsatile GH release. Tesamorelin contributes its clinically studied visceral-fat-reduction profile, CJC No DAC extends and strengthens the GH pulse without the prolonged GH “bleed” of the DAC version, and Ipamorelin adds selective GH release without meaningful cortisol or prolactin elevation.
— Tesamorelin 6 mg + Ipamorelin 6 mg + CJC-1295 No DAC 3 mg Blend Vial —
Reconstitute: Allow the lyophilized peptide, 0.6% acetic acid solution, and bacteriostatic water to reach room temperature first. Add 0.5 mL of 0.6% acetic acid solution to the vial and roll gently between your palms until no clumps of dry powder remain, then add 2.5 mL bacteriostatic water and roll gently until fully dissolved. The acetic acid cofactor helps prevent gelling. Hospira-brand BAC water is preferred for its consistent pH — pH variance from other vendors can denature the peptide.
Administration: Subcutaneous injection.
Timing: Dose at bedtime, on a fasted stomach, at least 90 minutes after your last meal.
Storage: Before reconstitution: refrigerate the lyophilized vial (up to 1 year). After reconstitution: store at room temperature — do NOT return the vial to the refrigerator (this has the greatest impact on preventing gelling). Keep away from sunlight or strong artificial light and avoid humid conditions. Use within 2 weeks of reconstitution.
Schedule: 5 consecutive dosing days followed by 2 rest days each week (5–7 days/week per protocol below).
Cycle Length: 12–16 week cycle, followed by a 4–8 week washout period. Shorter cycles will not yield tangible results — do not start this blend intending to “try it out” for 3–4 weeks.
Goal: Amplified pulsatile GH release for visceral fat reduction, recomposition, and recovery.
Standard Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–6 | 300 mcg Tesamorelin + 300 mcg Ipamorelin + 150 mcg CJC No DAC per day, 5–7 days/week | 15 units (0.15 mL) |
| Weeks 7–12+ | Remain at the same dose, 5–7 days/week for the rest of the cycle | 15 units (0.15 mL) |
Maximum Protocol
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–6 | 300 mcg Tesamorelin + 300 mcg Ipamorelin + 150 mcg CJC No DAC per day, 5–7 days/week | 15 units (0.15 mL) |
| Weeks 7–12+ | Increase to 25 units per day for the rest of the cycle | 25 units (0.25 mL) |
- Dual-receptor GH stimulation (GHRH-R + GHS-R) for amplified, pulsatile GH and IGF-1 output.
- Reduction of visceral (abdominal) adipose tissue — Tesamorelin’s primary studied effect.
- Selective GH release without significant cortisol or prolactin elevation (Ipamorelin).
- Preserves natural GH pulsatility (No-DAC CJC-1295 produces a shorter, cleaner pulse than the DAC version).
- Support for lean mass retention, recovery, and sleep-cycle GH pulse when dosed at bedtime.
While side effects are not common, you may experience:
- Irritation, redness, or swelling at the injection site
- Flushing or warmth after injection
- Water retention or joint aches (typical of elevated GH activity)
- Headache or light-headedness
- Numbness/tingling (paresthesia)
- Do not use when pregnant or nursing.
- Do not use with active malignancy — GH-axis stimulation is contraindicated with active cancer.
- Use caution with diabetes or impaired glucose tolerance — GH elevation can affect insulin sensitivity.
- Do not use with disrupted hypothalamic-pituitary function (e.g., pituitary tumor, hypophysectomy, head irradiation).
This blend is already a complete GHRH + GHRP stack. Common research pairings include:
- AOD-9604 – For additional fat-metabolism support
- BPC-157 / TB-500 (Wolverine) – Tissue repair alongside recomposition work
- 5-Amino-1MQ – Metabolic support during recomposition phases
PubMed-linked citations for verification. Many studies are animal/in-vitro.
- Metabolic effects of a growth hormone-releasing factor in patients with HIV (tesamorelin). N Engl J Med. 2007;357(23):2359-70. PMID: 18057338
- Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. PMID: 26457580
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
